Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib

In a phase Ib trial, afatinib plus cetuximab demonstrated promising clinical activity (objective response rate [ORR]: 29%; median progression-free survival [PFS]: 4.7 months) in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) with acquired r...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-11, Vol.113, p.51-58
Hauptverfasser:	Horn, Leora, Gettinger, Scott, Camidge, D. Ross, Smit, Egbert F., Janjigian, Yelena Y., Miller, Vincent A., Pao, William, Freiwald, Matthias, Fan, Jean, Wang, Bushi, Chand, Vikram K., Groen, Harry J.M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Afatinib Cetuximab EGFR NSCLC Phase Ib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!